Country
Germany
Germany-based Cardior Pharmaceuticals GmbH has announced positive results from a Phase 1b study of its lead compound CDR132L, an antisense oligonucleotide, for heart failure.
Full text available to subscribers only. Click here for information on subscribing to MedNous.